Epivir is designed to be part of combination antiretroviral therapy. It can be co-administered with other classes of HIV drugs (e.g., protease inhibitors, integrase inhibitors) as prescribed by a specialist. Drug-drug interaction checks should be performed to avoid additive toxicities, especially with didanosine or tenofovir.
If you remember the missed dose within 12 hours, take it promptly. If the next scheduled dose is due soon, skip the missed dose and resume your regular dosing schedule. Never double the dose to make up for a missed one.
Lamivudine is generally well-tolerated in patients with mild to moderate liver impairment. However, those with active hepatitis B or C should have regular liver function monitoring, as rare cases of hepatic decompensation have been reported.
Both lamivudine and tenofovir inhibit reverse transcriptase, but they have different chemical structures, dosing frequencies, and renal handling. Lamivudine is taken once daily at 150 mg, while tenofovir is usually taken once daily at 245 mg. Tenofovir may have a higher risk of renal toxicity, whereas lamivudine has a lower threshold for dose adjustment in renal impairment.
Lamivudine does not interfere with hormonal contraceptives. However, consistent use of an effective birth control method is recommended for women of child-bearing potential, as pregnancy planning should be discussed with a healthcare professional.
Yes, you can travel with Epivir. Carry the medication in its original packaging, include a copy of the prescription, and keep it in your hand luggage to avoid temperature extremes. Check the destination country’s import regulations for prescription medicines.
There are no specific dietary restrictions for lamivudine. Maintaining a balanced diet supports overall health, but you should avoid excessive alcohol intake, especially if you have co-existing hepatitis, to reduce liver strain.
Taking the tablet at the same time daily helps maintain steady drug levels and supports adherence to the overall antiretroviral regimen, which can improve viral suppression outcomes.
Symptoms include rapid breathing, persistent vomiting, abdominal pain, and unusual fatigue. Lactic acidosis is a medical emergency; seek immediate care if these signs develop.
Antiretroviral therapy is usually lifelong. Treatment duration is determined by viral load monitoring, CD4 count trends, and clinical response, all of which are evaluated regularly by an HIV specialist.
Epivir contains lamivudine as its active component. Lamivudine is an antiviral medication classified as a nucleoside reverse transcriptase inhibitor (NRTI) and is used primarily in the treatment of HIV infection. In the United Kingdom, Epivir is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as a film-coated pill containing 150 mg of lamivudine.
Lamivudine interferes with the replication cycle of HIV by mimicking the natural nucleoside cytidine. Once inside a cell, it is phosphorylated to its active triphosphate form, which then competes with the natural substrate for the viral reverse transcriptase enzyme. By incorporating into the growing viral DNA chain, lamivudine causes premature chain termination, preventing the virus from producing new copies of its genome. This mechanism reduces the amount of virus (viral load) in the bloodstream and helps preserve immune function.
Key pharmacological points:
Approved HIV Indications Epivir (lamivudine 150 mg) is approved by the MHRA for use as part of combination antiretroviral therapy (cART) in adults living with HIV-1 infection. It is recommended when a stable regimen containing at least two other antiretroviral agents is required to achieve and maintain viral suppression.
Typical Patient Profile
Note: Lamivudine is also approved in the UK for chronic hepatitis B infection, but that indication is listed under a different product name. The information below focuses on Epivir’s HIV use.
Lamivudine has demonstrated activity against hepatitis B virus (HBV) and is sometimes used off-label for chronic HBV infection. This use is not covered by the Epivir label in the UK and should be considered only under specialist supervision. Evidence from clinical trials shows that lamivudine can reduce HBV DNA levels, but long-term resistance may develop.
Off-label disclaimer: Off-label use requires medical supervision and individualized risk assessment.
These reactions are generally self-limiting and do not require discontinuation of therapy.
Lamivudine is a weak substrate of renal tubular secretion and has few clinically significant interactions, but patients should always disclose all concomitant medicines, including over-the-counter products and herbal supplements.
Patients should contact their healthcare professional if they experience persistent nausea, unexplained weight loss, or signs of lactic acidosis.
This article provides educational information about Epivir and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
